New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis

Principal Investigator

C. Michael Samson, MD

Enrollment Status:

Completed

Objective:

To evaluate the safety and efficacy of the 700 μg DEX PS DDS Applicator System (700 μg dexamethasone) compared with the 350 μg DEX PS DDS Applicator System (350 μg dexamethasone) in the treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate uveitis. (700 μg dexamethasone vs. 350 μg dexamethasone)

Study results are currently being analyzed. Please visit this webpage next month for the study update. For more information: ClinicalTrials.gov

 

Home > Current Research > Clinical Trials in Ophthalmology > Results > An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis